Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

 
• By Joseph Haas
SC1911_Candida-auris-fungi_1164101620_1200.jpg
Ibrexafungerp is being developed for acute and recurrent VVC

More from Strategy

More from Business